Regulus Therapeutics has entered into a pharma partnering strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development.
Under the terms of the pharma partnering agreement, AstraZeneca will make a $28M payment which includes an equity investment and an upfront payment to Regulus.
Regulus and AstraZeneca will collaborate on three microRNA targets, which include Regulus’ lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis.
AstraZeneca will lead and fund the clinical development and commercialization of these programs.
In addition, Regulus could also receive clinical milestones based on the successful development of microRNA therapies in each target area.
Regulus is also eligible to receive significant launch and commercial milestone payments and royalties contingent on the successful commercialization of microRNA therapeutic products by AstraZeneca.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity